BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11049969)

  • 1. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.
    Press OW; Eary JF; Gooley T; Gopal AK; Liu S; Rajendran JG; Maloney DG; Petersdorf S; Bush SA; Durack LD; Martin PJ; Fisher DR; Wood B; Borrow JW; Porter B; Smith JP; Matthews DC; Appelbaum FR; Bernstein ID
    Blood; 2000 Nov; 96(9):2934-42. PubMed ID: 11049969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
    Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
    J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
    J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloablative I-131-tositumomab with escalating doses of fludarabine and autologous hematopoietic transplantation for adults age ≥ 60 years with B cell lymphoma.
    Gopal AK; Gooley TA; Rajendran JG; Pagel JM; Fisher DR; Maloney DG; Appelbaum FR; Cassaday RD; Shields A; Press OW
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):770-5. PubMed ID: 24530971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
    Chow VA; Rajendran JG; Fisher DR; Appelbaum FR; Cassaday RD; Martin PS; Holmberg LA; Gooley TA; Stevenson PA; Pagel JM; Green DJ; Press OW; Gopal AK
    Am J Hematol; 2020 Jul; 95(7):775-783. PubMed ID: 32243637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.
    Gopal AK; Rajendran JG; Petersdorf SH; Maloney DG; Eary JF; Wood BL; Gooley TA; Bush SA; Durack LD; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
    Blood; 2002 May; 99(9):3158-62. PubMed ID: 11964278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial.
    Vose JM; Carter S; Burns LJ; Ayala E; Press OW; Moskowitz CH; Stadtmauer EA; Mineshi S; Ambinder R; Fenske T; Horowitz M; Fisher R; Tomblyn M
    J Clin Oncol; 2013 May; 31(13):1662-8. PubMed ID: 23478060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.
    Wagner JY; Schwarz K; Schreiber S; Schmidt B; Wester HJ; Schwaiger M; Peschel C; von Schilling C; Scheidhauer K; Keller U
    Oncotarget; 2013 Jun; 4(6):899-910. PubMed ID: 23765188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
    Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
    Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.
    Liu SY; Eary JF; Petersdorf SH; Martin PJ; Maloney DG; Appelbaum FR; Matthews DC; Bush SA; Durack LD; Fisher DR; Gooley TA; Bernstein ID; Press OW
    J Clin Oncol; 1998 Oct; 16(10):3270-8. PubMed ID: 9779701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
    Nademanee A; Forman S; Molina A; Fung H; Smith D; Dagis A; Kwok C; Yamauchi D; Anderson AL; Falk P; Krishnan A; Kirschbaum M; Kogut N; Nakamura R; O'donnell M; Parker P; Popplewell L; Pullarkat V; Rodriguez R; Sahebi F; Smith E; Snyder D; Stein A; Spielberger R; Zain J; White C; Raubitschek A
    Blood; 2005 Oct; 106(8):2896-902. PubMed ID: 16002426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
    Srivastava S; Jones D; Wood LL; Schwartz JE; Nelson RP; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Robertson MJ; Farag SS
    Biol Blood Marrow Transplant; 2011 Jul; 17(7):987-94. PubMed ID: 20965266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.
    Press OW; Eary JF; Appelbaum FR; Martin PJ; Nelp WB; Glenn S; Fisher DR; Porter B; Matthews DC; Gooley T
    Lancet; 1995 Aug; 346(8971):336-40. PubMed ID: 7623531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
    Vose JM; Bierman PJ; Loberiza FR; Enke C; Hankins J; Bociek RG; Chan WC; Weisenburger DD; Armitage JO
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):123-8. PubMed ID: 22940055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
    N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.
    Gopal AK; Gooley TA; Maloney DG; Petersdorf SH; Eary JF; Rajendran JG; Bush SA; Durack LD; Golden J; Martin PJ; Matthews DC; Appelbaum FR; Bernstein ID; Press OW
    Blood; 2003 Oct; 102(7):2351-7. PubMed ID: 12750161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
    Decaudin D; Mounier N; Tilly H; Ribrag V; Ghesquières H; Bouabdallah K; Morschhauser F; Coiffier B; Le Gouill S; Bologna S; Delarue R; Huynh A; Bosly A; Brière J; Gisselbrecht C
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):212-8. PubMed ID: 21575926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous stem cell transplant salvage therapy for relapsed/refractory aggressive non-Hodgkin lymphoma.
    Kruger PC; Cooney JP; Turner JH
    Cancer Biother Radiopharm; 2012 Nov; 27(9):552-60. PubMed ID: 23062193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
    Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
    Shimoni A; Zwas ST
    Semin Nucl Med; 2016 Mar; 46(2):119-25. PubMed ID: 26897716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.